Hana Asset Management Launches First Medical AI ETF
Hana Asset Management has launched the world's first 1Q US Medical AI ETF. This ETF invests in leading US medical AI companies such as TempusAI, Recursion Pharmaceuticals, and Intuitive Surgical, tracking the KEDI US Medical AI Index. The medical AI market is projected to grow significantly from $26.7 billion in 2024 to $613.8 billion by 2033, with an estimated annual growth rate of about 37%.
CEO Kim Tae-woo stated plans to continuously launch ETFs expecting long-term growth through integration with the AI industry. This ETF stands out by targeting the North American market, selecting up to 15 prominent medical AI companies, amidst growing interest spurred by Google AlphaFold2's influence on the medical AI field.
Hana Asset Management is expanding its diverse ETF portfolio, appealing not only to pension investors but also to those interested in innovative industries. This strategic move reflects the company's commitment to maximizing investment opportunities in the rapidly expanding medical AI market.
Related News
Hana Asset Management, World's First '1Q USA Medical AI ETF' Listing - E-todayHana Asset Management announced on the 22nd that it will newly list the '1Q USA Medical AI Exchange-Traded Fund (ETF)', which invests in leading US Medical AI companies anticipated to benefit from the AI industry.
뉴스핌2025 7月 22
Hana Asset Management, World's First 1Q U.S. Medical AI ETF New Listing - NewsPim[Seoul=NewsPim] Reporter Song Ki-wook = Hana Asset Management announced on the 22nd that it will list the 1Q U.S. Medical AI ETF for the first time globally. This new product is expected to benefit from the AI industry.
Hana Asset Management, new listing of 1Q US Medical AI ETF - meconomynews.comHana Asset Management announced on the 22nd that it will newly list the 1Q US Medical AI ETF (Exchange Traded Fund). This newly listed product invests in leading US Medical AI companies such as Tempus AI, Recursion Pharmaceuticals, and Intuitive Surgical, which are expected to benefit from the AI (artificial intelligence) industry. The Medical AI industry started when Google's AlphaFold2 accurately predicted protein structures that were difficult to predict using existing methods by utilizing AI technology. This opened new possibilities in various fields such as new drug development and protein function research, and attracted great interest by even winning the Nobel Prize in Chemistry last year. Recently, including Jensen Huang's Nvidia
화이트페이퍼2025 7月 22
Hana Asset Management to List 'World's First' 1Q US Medical AI ETF - Whitepaper[Whitepaper=Go SooAh, Reporter] Hana Asset Management (CEO Kim TaeWoo) announced on the 22nd that it will newly list the 1Q US Medical AI ETF (0083S0), the world's first of its kind. This ETF invests in US Medical AI and tracks the 'KEDI US Medical AI' index. The index selects up to 15 US publicly listed companies with high relevance to medical (healthcare) AI using scoring and other comprehensive methods. Major included stocks are Tempus AI (TEM), an AI-based precision medical (diagnostic) platform company known as the 'Palantir of Healthcare', and Recursion Pharmaceuticals (RXR), an AI drug development firm in which Nvidia has invested.